Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Infantile Hemangiomas: Challenging Cases and Controversies
Description
Dr. Sheila McGuinness from the University of Minnesota presented a talk on infantile hemangiomas, discussing challenging cases and associated controversies. The presentation highlighted two complex cases: one involving a seven-week-old girl with segmental hemangiomas affecting both upper and lower body regions and another case involving a patient who showed limited response to traditional therapies. In the first case, the risks of FACE syndrome and lumbar syndrome were explored, emphasizing the importance of comprehensive diagnostic work-ups including MRI and ultrasound for associated anomalies. The presentation detailed the management of ulceration in hemangiomas, noting that some patients might experience worsening symptoms with standard doses of propranolol, prompting consideration of dosage adjustments. The second case illustrated the challenges of treating a stubborn hemangioma, where despite high doses of propranolol and the addition of serolimus, no significant improvement was observed. Ultimately, surgical intervention and steroid approaches were explored as viable options. McGuinness stressed the critical need for a multidisciplinary approach in managing complicated cases of infantile hemangiomas, concluding with a call to utilize pediatric dermatology resources for better outcomes.
View moreConclusions
- Segmental infantile hemangiomas of the upper or lower body are linked to complex anomalies, specifically in cases of PHACE or LUMBAR syndromes.
- Contemporary clinical practices suggest considering a lower dose of propranolol for healing ulcerations in segmental infantile hemangiomas.
- A minority of infantile hemangiomas do not respond to traditional therapies like beta blockers, highlighting the need for a multidisciplinary treatment approach to optimize patient outcomes.
- The research reveals that ulceration in infantile hemangiomas may worsen with standard dose initiation or escalation of propranolol, necessitating a cautious approach in treatment.
- Sirolimus can be a safe adjunct medication, but its effectiveness varies and requires further clinical studies to establish clear benefits in treating hemangiomas.
- Garzon MC, Epstein LG, Heyer et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016 Nov; 178:24-33.e2.
- Metry D, Heyer G, Hess C, et al. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009 Nov 1;124(5):1447-56.
- Shayegan, Leila H ., et al. Journal of Vascular Anomalies 3.3 (2022)
- Fernández Faith E, Shah S, Witman PM, Harfmann K, Bradley F et al. Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma. JAMA Dermatol. 2021 May 1;157(5):566-572.
- Cho YJ, Kwon H, Kwon et al. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience. J Vasc Surg Venous Lymphat Disord. 2021 Nov;9(6):1488-1494.
- Dávila-Osorio VL, Iznardo H, Roé E, Puig L, Baselga E. Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatr Dermatol. 2020 Jul;37(4):684-686. doi: 10.1111/pde.14163. Epub 2020 Apr 23. PMID: 32323340.
- Greenberger, S. et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J. Investig. Dermatol.131, 2467-2476 (2011).
- Pediatric Research (2023) 93:1470-1479; https://doi.org/10.1038/s41390-022-02325-z